• Reversing an overdose keeps a person alive tonight. It says nothing about next month. A survey published in October 2026 asks a simple question. Would people who use opioids accept a treatment that could help with that next step? It also raises a practical question about naltrexone implants. They are an older form of long acting blockade with a trial record of their own. This review weighs the survey on its merits, then asks what it can and cannot tell us.

    What the Researchers Did
    The paper appeared ahead of print in the Journal of Addiction Medicine. A team including Emily Herberholz, Sandra Comer and David Epstein began from a dispute. Patient advocates and online commentators have called immunotherapy for opioid use disorder fundamentally misguided. The team decided to ask the people most affected.

    They ran a survey experiment between June 2024 and June 2025. The sample was 442 US adults. All had used opioids nonmedically in the past six months or had taken methadone or buprenorphine for opioid use disorder. Respondents averaged 38.9 years of age, and 52.7% were women. They met eight of the 11 DSM 5 criteria for the disorder on average.

    Chance assigned each person to one of three survey versions. Two described the treatment as a vaccine, one with minimal information and one with more detail. The third described a long acting medication. Researchers then asked about willingness to use a long acting blockade. That treatment matched each person’s preferred duration and targeted drugs, such as heroin, fentanyl, methamphetamine, cannabis or nicotine.

    What the Survey Found
    Willingness was high across the board, but the wording moved it. In the medication version, 134 of 150 respondents (89%) said they were very or kind of willing. The vaccine with minimal information drew 108 of 142 (76%). Adding more detail left the figure at 113 of 150 (75%). Extra information changed almost nothing. The label changed a lot, by about 13 points.

    Respondents also set limits. They preferred protection lasting under a year, aimed mainly at fentanyl. The authors conclude that people want control over duration and breadth. Uptake may rise if products come in a range of both.

    How Strong Is the Evidence?
    Randomising the wording is the survey’s best feature. Chance decided who saw which version. So the gap between the medication and vaccine labels is unlikely to reflect differences between groups. The sample also reaches people that policy debates often discuss and rarely ask, including those still using opioids nonmedically.

    Several limits still need weight. First, willingness is not behaviour. Telling a researcher you would take a treatment costs nothing, and taking it does. The authors themselves hedge their conclusion on uptake.
    Second, the main outcome bent to each respondent’s wishes. Respondents described a product with their own preferred duration and targets. The 89% therefore measures interest in an ideal product, not a real one with fixed features. Real products will rarely match each person’s wishes.

    Third, the abstract leaves gaps. The abstract does not say how the team recruited people. Nor does it say how the sample divides between people using opioids nonmedically and people already in treatment. It also leaves open whether the gaps between versions reached statistical significance. The full paper may answer those questions, and readers should check before leaning on the percentages.

    Fourth, the minority matters. Between 11% and 25% of respondents, depending on the version, did not say they were very or kind of willing. The abstract does not say why, yet their reasons would shape real world uptake.

    What the Survey Means for Naltrexone Implants
    This survey did not test naltrexone implants. It does show an appetite for a blockade that lasts months. That is where sustained release naltrexone enters the picture. Kunøe, Lobmaier, Ngo and Hulse wrote a 2012 review in the British Journal of Clinical Pharmacology. It describes implants made of small biodegradable pellets placed under the skin. The Australian version releases naltrexone for as long as seven months. That sits inside the under one year range respondents preferred.

    The trial record for naltrexone implants is encouraging. Most randomised trials in the review showed more heroin abstinence with sustained release naltrexone than with controls. The typical drop in opioid use was about 50% against oral naltrexone or usual care. Results varied widely between patients. The review also described a registry study in which overdose admissions among implant patients fell to zero.

    A 2015 Dalgarno Institute paper adds detail. It cites a Norwegian trial of 56 people after detoxification. Over 180 days, implant patients averaged 45 fewer days of heroin use than controls. A second trial of 70 patients saw more people on oral naltrexone return to regular heroin use by six months.

    Both documents press on the exit question. The review notes that people who reach stable lives on opioid maintenance have no validated alternative to lifelong daily dosing. Dalgarno’s paper took that gap to policy makers. It asked for exit strategies in methadone programmes and for urgent trials of naltrexone implants.

    Why Survival Alone Falls Short
    A letter in the journal Addiction, by Nathaniel Day and colleagues, explains why the next step cannot wait. Naloxone does not reverse brain damage. An overdose that cuts off oxygen can injure the brain, and repeated episodes are likely to compound the harm. The authors cite British Columbia data. Within a year of a first overdose, adults faced a 6% risk of diagnosed brain injury. For people under 19, the risk was 10%.
    The letter is short, and its authors admit the research is still emerging. Many non fatal overdoses are never clinically assessed, so recorded cases probably understate the problem. Their conclusion is still plain. Resuscitation is not a sufficient end point. Prescribers should favour long acting injectable options like naltrexone or buprenorphine for patients at risk of treatment related cognitive decline. They also warn against dosing schedules that tax memory. Naltrexone implants fit that advice on its face.

    Where the Evidence on Naltrexone Implants Falls Short
    The implant evidence has real limits. Its authors call the findings on sustained release naltrexone promising and ask for more studies, especially against standard treatments and in pregnancy. Site reactions such as itching, redness or skin infection occurred in 2 to 5% of implant patients. In extreme cases, the implant may need removal. One author also declared a research contract with the implant’s manufacturer.

    The sharpest warning concerns fentanyl. Naltrexone implants block receptors by competing with opioids. The review accepts that extreme quantities of opioids, or potent synthetics such as fentanyl, can outperform that competition. It also notes case reports of patients overcoming the blockade. Yet fentanyl was the drug respondents most wanted a blockade to cover. The review dates from 2012, and most of the trial evidence is older still. Naltrexone implants have no trial record against that drug supply in the studies described here.

    A Fair Conclusion
    Put the evidence side by side and a modest position emerges. Overdose reversal is necessary and not sufficient. The Addiction letter shows that survival can carry a brain injury. Meanwhile, the survey shows that most people who use opioids would consider a long acting blockade, particularly as a medication. Older trials suggest naltrexone implants can cut opioid use.

    None of this proves that naltrexone implants work for today’s patients. It does justify the trial the Dalgarno paper requested in 2015. That work would need modern designs and direct comparisons with standard treatments. It would also need participants exposed to fentanyl, plus measures of both exit from use and brain health. Until then, a rescue should be the start of treatment, not the end of it.

    Prepared by WRD News Team


    Sources

This is what you will find on the NoBrainer Website

NoBrainer Education
Find a range of teaching/learning as well as coaching tools for educators of all types. Assisting you to build resilience into your community/school/family setting and better understand best-practice around AOD issues
NoBrainer Resources
Find here a range of resources that you can connect with to help you navigate many of the issues of AOD Use
NoBrainer News
Find out what is happening in the world of alcohol & other drugs, Lots of useful articles for you to read.
NoBrainer Videos
Check out our selection of video clips on various AOD issues to assist you in getting better perspective